Ken Frazier, Merck CEO (Bess Adler/Bloomberg via Getty Images)

Mer­ck­'s Keytru­da blazes a path in first-line cer­vi­cal can­cer, mak­ing good on drug­mak­er's push for ear­li­er pa­tients

In the years since I/O won­der drug Keytru­da’s ini­tial ap­proval, Mer­ck has struck an ag­gres­sive clin­i­cal tri­al pro­gram, which is now firm­ly fo­cused on ear­li­er lines of ther­a­py. The drug­mak­er has scored some suc­cess there so far, and now it’s earned one of its biggest wins yet.

Keytru­da plus chemother­a­py with or with­out back­ground Avastin sig­nif­i­cant­ly ex­tend­ed pa­tients’ lives over those dosed with a place­bo con­trol in first-line pa­tients with per­sis­tent, re­cur­rent or metasta­t­ic cer­vi­cal can­cer, ac­cord­ing to top-line da­ta from the Phase III KEYNOTE-826 study re­vealed Tues­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA